Sanofi Could Get Boost From Dupixent U.S. Price -- Market Talk

Dow Jones04-10

1052 GMT - Sanofi's first-quarter results could get a boost from the U.S. net price of its Dupixent blockbuster drug jointly developed with Regeneron Pharmaceuticals, analysts at UBS say in a research note. The French drugmaker has signaled Dupixent U.S. prices in the first quarter won't see step down associated with increased patient copay assistance, while prescription data point to continued strong demand, according to UBS. "This trend is a surprise to us, and industry experts we have talked to," the analysts say. "We assume that this is likely a temporary event driven by prior rebate adjustments or reduced from free drug from recent launches [like chronic obstructive pulmonary disease] following updated insurance coverage." UBS estimates Dupixent first-quarter sales at 3.97 billion euros, out of 10.24 billion euros for the group overall. Shares rise 0.4%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

April 10, 2026 06:54 ET (10:54 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626914041?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-10 18:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626914041","market":"sh","top_or_hot":-1,"title":"Sanofi Could Get Boost From Dupixent U.S. Price -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1052 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>'s first-quarter results could get a boost from the U.S. net price of its Dupixent blockbuster drug jointly developed with Regeneron Pharmaceuticals, analysts at UBS say in a research note. The French drugmaker has signaled Dupixent U.S. prices in the first quarter won't see step down associated with increased patient copay assistance, while prescription data point to continued strong demand, according to UBS. \"This trend is a surprise to us, and industry experts we have talked to,\" the analysts say. \"We assume that this is likely a temporary event driven by prior rebate adjustments or reduced from free drug from recent launches [like chronic obstructive pulmonary disease] following updated insurance coverage.\" UBS estimates Dupixent first-quarter sales at 3.97 billion euros, out of 10.24 billion euros for the group overall. Shares rise 0.4%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 10, 2026 06:54 ET (10:54 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Could Get Boost From Dupixent U.S. Price -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Could Get Boost From Dupixent U.S. Price -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-10 18:54</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1052 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>'s first-quarter results could get a boost from the U.S. net price of its Dupixent blockbuster drug jointly developed with Regeneron Pharmaceuticals, analysts at UBS say in a research note. The French drugmaker has signaled Dupixent U.S. prices in the first quarter won't see step down associated with increased patient copay assistance, while prescription data point to continued strong demand, according to UBS. \"This trend is a surprise to us, and industry experts we have talked to,\" the analysts say. \"We assume that this is likely a temporary event driven by prior rebate adjustments or reduced from free drug from recent launches [like chronic obstructive pulmonary disease] following updated insurance coverage.\" UBS estimates Dupixent first-quarter sales at 3.97 billion euros, out of 10.24 billion euros for the group overall. Shares rise 0.4%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 10, 2026 06:54 ET (10:54 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNY","symbol_name":"赛诺菲安万特","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2626914041","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2626914041","pubTimestamp":1775818440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1052 GMT - Sanofi's first-quarter results could get a boost from the U.S. net price of its Dupixent blockbuster drug jointly developed with Regeneron Pharmaceuticals, analysts at UBS say in a research note. The French drugmaker has signaled Dupixent U.S. prices in the first quarter won't see step down associated with increased patient copay assistance, while prescription data point to continued strong demand, according to UBS. \"This trend is a surprise to us, and industry experts we have talked to,\" the analysts say. \"We assume that this is likely a temporary event driven by prior rebate adjustments or reduced from free drug from recent launches [like chronic obstructive pulmonary disease] following updated insurance coverage.\" UBS estimates Dupixent first-quarter sales at 3.97 billion euros, out of 10.24 billion euros for the group overall. Shares rise 0.4%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNY":"赛诺菲安万特","BK4588":"碎股","BK4585":"ETF&股票定投概念","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","SNYNF":"Sanofi","BK4007":"制药"},"translate_title":"赛诺菲可能会从Dupixent美国价格中获得提振——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":0.9,"SNYNF":1.5},"content_text":"1052 GMT - Sanofi's first-quarter results could get a boost from the U.S. net price of its Dupixent blockbuster drug jointly developed with Regeneron Pharmaceuticals, analysts at UBS say in a research note. The French drugmaker has signaled Dupixent U.S. prices in the first quarter won't see step down associated with increased patient copay assistance, while prescription data point to continued strong demand, according to UBS. \"This trend is a surprise to us, and industry experts we have talked to,\" the analysts say. \"We assume that this is likely a temporary event driven by prior rebate adjustments or reduced from free drug from recent launches [like chronic obstructive pulmonary disease] following updated insurance coverage.\" UBS estimates Dupixent first-quarter sales at 3.97 billion euros, out of 10.24 billion euros for the group overall. Shares rise 0.4%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 10, 2026 06:54 ET (10:54 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626914041","isCrawlerRequest":true}